Anti-CREL1/ CRELD1/ AVSD2 functional antibody

Anti-CREL1/ CRELD1/ AVSD2 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to CRELD1/CRELD1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0123-Ab-1/ GM-Tg-hg-SE0123-Ab-2Anti-Human CRELD1 monoclonal antibodyHuman
GM-Tg-rg-SE0123-Ab-1/ GM-Tg-rg-SE0123-Ab-2Anti-Rat CRELD1 monoclonal antibodyRat
GM-Tg-mg-SE0123-Ab-1/ GM-Tg-mg-SE0123-Ab-2Anti-Mouse CRELD1 monoclonal antibodyMouse
GM-Tg-cynog-SE0123-Ab-1/ GM-Tg-cynog-SE0123-Ab-2Anti-Cynomolgus/ Rhesus macaque CRELD1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0123-Ab-1/ GM-Tg-felg-SE0123-Ab-2Anti-Feline CRELD1 monoclonal antibodyFeline
GM-Tg-cang-SE0123-Ab-1/ GM-Tg-cang-SE0123-Ab-2Anti-Canine CRELD1 monoclonal antibodyCanine
GM-Tg-bovg-SE0123-Ab-1/ GM-Tg-bovg-SE0123-Ab-2Anti-Bovine CRELD1 monoclonal antibodyBovine
GM-Tg-equg-SE0123-Ab-1/ GM-Tg-equg-SE0123-Ab-2Anti-Equine CRELD1 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0123-Ab-1/ GM-Tg-hg-SE0123-Ab-2; GM-Tg-rg-SE0123-Ab-1/ GM-Tg-rg-SE0123-Ab-2;
GM-Tg-mg-SE0123-Ab-1/ GM-Tg-mg-SE0123-Ab-2; GM-Tg-cynog-SE0123-Ab-1/ GM-Tg-cynog-SE0123-Ab-2;
GM-Tg-felg-SE0123-Ab-1/ GM-Tg-felg-SE0123-Ab-2; GM-Tg-cang-SE0123-Ab-1/ GM-Tg-cang-SE0123-Ab-2;
GM-Tg-bovg-SE0123-Ab-1/ GM-Tg-bovg-SE0123-Ab-2; GM-Tg-equg-SE0123-Ab-1/ GM-Tg-equg-SE0123-Ab-2
Products NameAnti-CRELD1 monoclonal antibody
Formatmab
Target NameCRELD1
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CRELD1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0123-Ag-1Recombinant multi-species CREL1/ CRELD1/ AVSD2 protein


    Target information

    Target IDGM-SE0123
    Target NameCRELD1
    Gene ID78987,171508,312638,699345,610107,101085107,504854,100051995
    Gene Symbol and SynonymsAVSD2,CIRRIN,CRELD1,i11E7
    Uniprot AccessionQ96HD1,Q4V7F2,Q5EA46
    Uniprot Entry NameCREL1_HUMAN,CREL1_RAT,CREL1_BOVIN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000163703
    Target ClassificationN/A

    The target: CRELD1, gene name: CRELD1, also named as AVSD2, CIRRIN. This gene encodes a member of a subfamily of epidermal growth factor-related proteins. The encoded protein is characterized by a cysteine-rich with epidermal growth factor-like domain. This protein may function as a cell adhesion molecule. Mutations in this gene are the cause of atrioventricular septal defect. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Apr 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.